Skip to main content

Day: March 2, 2024

Scilex Holding Company Announces that the Official Committee of Unsecured Creditors of Sorrento Therapeutics, Inc., has Filed a Motion with the U.S. Bankruptcy Court to Extend the Lockup Period on Shares of Scilex Stock Previously Distributed by Sorrento to its Stockholders as a Dividend from March 31, 2024 to September 30, 2024

PALO ALTO, Calif., March 02, 2024 (GLOBE NEWSWIRE) — Scilex Holding Company (Nasdaq: SCLX, “Scilex”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced that the Official Committee of Unsecured Creditors (the “Creditors’ Committee”) of Sorrento Therapeutics, Inc. (OTC: SRNEQ, “Sorrento”) has filed a motion (the “Motion”) with the U.S. Bankruptcy Court for the Southern District of Texas (the “Court”) seeking to further extend the restrictions on transfer on the shares of common stock of Scilex that were previously distributed by Sorrento to its stockholders as a dividend on January 19, 2023 (the “Dividend Stock”) from March 31, 2024 to September 30, 2024. Further notice related to the U.S. Bankruptcy...

Continue reading

Ultimovacs announces publication of results from NIPU Phase II trial with UV1 vaccination in mesothelioma in European Journal of Cancer

NON-REGULATORY PRESS RELEASEThe NIPU trial is investigating the effect of adding UV1 vaccine to immunotherapy as second-line treatment of pleural mesothelioma. The results were initially presented at the ESMO Conference in October 2023 The publication outlines the full trial results, including observations on UV1’s positive impact on objective response rate, overall survival, and additional data on increased efficacy in defined histological subtypesOslo, March 2, 2024: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines, today announced that the results from the randomized controlled Phase II clinical trial, NIPU, are published in the European Journal of Cancer. The trial investigates the effect of adding Ultimovacs’ cancer vaccine UV1 to second-line treatment...

Continue reading

Brookfield Business Partners Completes 2023 Annual Filings

BROOKFIELD, NEWS, March 01, 2024 (GLOBE NEWSWIRE) — Brookfield Business Partners (NYSE: BBU, BBUC; TSX: BBU.UN, BBUC) announced today the filing of its 2023 annual reports, including its audited financial statements for the year ended December 31, 2023, on Forms 20-F with the SEC on EDGAR as well as with the Canadian securities authorities on SEDAR+. These documents are also available on our website at https://bbu.brookfield.com (or for Brookfield Business Corporation, at https://bbu.brookfield.com/bbuc/overview) in the Reports & Filings section, on SEC’s website at www.sec.gov and on the SEDAR+ website at www.sedarplus.ca. Hard copies will be provided to unitholders and shareholders free of charge upon request. Brookfield Business Partners is a global business services and industrials company focused on owning and operating...

Continue reading

Passing of the Right Honorable Brian Mulroney

TORONTO, March 01, 2024 (GLOBE NEWSWIRE) — The Board of Barrick Gold Corporation (NYSE:GOLD)(TSX:ABX) is deeply saddened by the passing of the Chairman of its International Advisory Board and former member of the Barrick Board of Directors, the Right Honorable Brian Mulroney, on February 29, 2024. Prime Minister of Canada from 1984 to 1993, Mr Mulroney holds the distinction of being the first Canadian Prime Minister in 35 years to win successive majority governments and the first Conservative Prime Minister to do so in 100 years. Best known for his stance on international trade and building the closest of relationships with the United States of America, United Kingdom and Germany, Mr Mulroney also served as Co-Chairman of the United Nation’s World Summit for Children. His government played leading roles in the campaign against...

Continue reading

Earth Alive announces the departure of its Chief Legal Officer

MONTREAL, March 01, 2024 (GLOBE NEWSWIRE) — Earth Alive Clean Technologies Inc. (TSXV: EAC) (“Earth Alive” or the “Company”), a leading provider of environmentally friendly microbial products, announced the departure of Eric Paul-Hus, Chief Legal Officer, effective March 1st, 2024. Eric has brought his legal expertise and counsel to numerous initiatives and projects. “We thank Eric for his contribution and dedication during his tenure at Earth Alive,” expressed Nikolaos Sofronis, CEO of Earth Alive. “We wish him all the best in his future endeavors.” Eric remains available for future developments within the company. About Earth Alive Clean Technologies Inc. Earth Alive is a leader in the field of microorganism-based technologies. Earth Alive’s innovative products contribute...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.